oxybutynin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
spasmolytics with a papaverine-like action 2028 5633-20-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • oxybutynin hydrochloride
  • oxybutynin
  • oxybutynin chloride
  • oxytrol
  • ditropan
  • kentera
  • oxybutynin HCl
Oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. Oxybutynin is a racemic (50:50) mixture of R- and S-isomers. Antimuscarinic activity resides predominantly in the R-isomer. The R-isomer of oxybutynin shows greater selectivity for the M1 and M3 muscarinic subtypes (predominant in bladder detrusor muscle and parotid gland) compared to the M2 subtype (predominant in cardiac tissue).
  • Molecular weight: 357.49
  • Formula: C22H31NO3
  • CLOGP: 4.69
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 49.77
  • ALOGS: -4.55
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O
3.90 mg TD

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.80 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.93 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 6 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.85 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 16, 1975 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 222.46 10.28 219 37652 41906 46606285
Urinary tract infection 205.04 10.28 510 37361 219756 46428435
Fall 186.65 10.28 638 37233 328459 46319732
Multiple sclerosis 118.19 10.28 122 37749 24669 46623522
Urinary incontinence 110.80 10.28 126 37745 28404 46619787
Application site erythema 93.47 10.28 55 37816 4849 46643342
Dry mouth 89.28 10.28 160 37711 54766 46593425
Urine analysis abnormal 64.51 10.28 41 37830 4149 46644042
Gait disturbance 63.87 10.28 260 37611 145003 46503188
Rheumatoid arthritis 54.44 10.28 69 37802 240146 46408045
Balance disorder 52.17 10.28 142 37729 64379 46583812
Exposure during pregnancy 50.03 10.28 13 37858 108199 46539992
Micturition urgency 49.54 10.28 45 37826 7772 46640419
Laboratory test abnormal 47.03 10.28 74 37797 22773 46625418
Application site pruritus 46.70 10.28 33 37838 3980 46644211
Maternal exposure during pregnancy 44.30 10.28 14 37857 102535 46545656
Neurogenic bladder 41.17 10.28 27 37844 2883 46645308
Secondary progressive multiple sclerosis 41.12 10.28 20 37851 1200 46646991
Bladder disorder 39.57 10.28 38 37833 7040 46641151
Pollakiuria 38.54 10.28 70 37801 24191 46624000
Hypertonic bladder 38.00 10.28 26 37845 2978 46645213
Product adhesion issue 36.36 10.28 31 37840 4924 46643267
Systemic lupus erythematosus 33.85 10.28 6 37865 65174 46583017
Urine leukocyte esterase positive 32.20 10.28 22 37849 2513 46645678
Culture urine positive 30.75 10.28 24 37847 3367 46644824
Joint swelling 30.53 10.28 55 37816 166018 46482173
Muscular weakness 30.25 10.28 151 37720 91693 46556498
Mental status changes 29.95 10.28 83 37788 38005 46610186
Incontinence 29.22 10.28 38 37833 9824 46638367
White blood cells urine positive 28.76 10.28 25 37846 4075 46644116
Confusional state 28.22 10.28 224 37647 159668 46488523
Escherichia urinary tract infection 27.86 10.28 38 37833 10285 46637906
Malignant neoplasm progression 27.79 10.28 9 37862 64917 46583274
Band neutrophil percentage increased 26.88 10.28 9 37862 201 46647990
Dysuria 26.33 10.28 65 37806 27768 46620423
Monocyte percentage increased 26.14 10.28 14 37857 1029 46647162
Febrile neutropenia 26.08 10.28 23 37848 94604 46553587
Gait inability 25.05 10.28 74 37797 35129 46613062
Off label use 25.01 10.28 193 37678 379648 46268543
Application site rash 25.00 10.28 19 37852 2563 46645628
Myelocyte percentage increased 24.53 10.28 8 37863 164 46648027
Cerebral atrophy 23.90 10.28 24 37847 4692 46643499
Bacterial test 23.84 10.28 14 37857 1229 46646962
Urinary sediment present 23.61 10.28 16 37855 1804 46646387
Synovitis 23.56 10.28 10 37861 61065 46587126
Muscle spasticity 23.46 10.28 37 37834 11403 46636788
Urine oxalate increased 23.27 10.28 8 37863 194 46647997
Abortion spontaneous 22.70 10.28 4 37867 43642 46604549
Red blood cells urine positive 22.66 10.28 18 37853 2589 46645602
Band neutrophil count increased 22.59 10.28 9 37862 333 46647858
Prescription drug used without a prescription 22.29 10.28 14 37857 1388 46646803
Cystitis 22.13 10.28 80 37791 42161 46606030
Bladder spasm 21.60 10.28 14 37857 1465 46646726
Hallucination 21.58 10.28 89 37782 49862 46598329
Dysmetropsia 21.15 10.28 6 37865 75 46648116
Crystal urine present 21.09 10.28 13 37858 1246 46646945
Injection site scar 21.05 10.28 11 37860 769 46647422
Treatment failure 20.77 10.28 27 37844 93060 46555131
Urinary retention 20.69 10.28 57 37814 26004 46622187
Retinal depigmentation 20.67 10.28 8 37863 274 46647917
Hallucination, visual 20.48 10.28 45 37826 17828 46630363
Food refusal 20.42 10.28 8 37863 283 46647908
Specific gravity urine decreased 20.31 10.28 9 37862 436 46647755
Neutropenia 20.09 10.28 55 37816 143149 46505042
Asthenia 20.06 10.28 359 37512 310716 46337475
Lymphocyte percentage decreased 20.04 10.28 17 37854 2682 46645509
Depression 19.77 10.28 218 37653 169886 46478305
Psychotic symptom 19.46 10.28 11 37860 899 46647292
Toxicity to various agents 19.42 10.28 97 37774 211669 46436522
Urinary tract infection bacterial 18.95 10.28 20 37851 4145 46644046
Myelocyte count increased 18.80 10.28 8 37863 351 46647840
Dementia 18.73 10.28 39 37832 14891 46633300
Amnesia 18.64 10.28 75 37796 41556 46606635
Lymphocyte count decreased 18.40 10.28 54 37817 25535 46622656
Thrombocytopenia 18.22 10.28 48 37823 126533 46521658
Drug intolerance 18.10 10.28 60 37811 146989 46501202
Hepatic enzyme increased 17.97 10.28 24 37847 81763 46566428
Chronic papillomatous dermatitis 17.81 10.28 5 37866 60 46648131
Head injury 17.73 10.28 52 37819 24584 46623607
Product administered at inappropriate site 17.67 10.28 15 37856 2368 46645823
Nocturia 17.38 10.28 25 37846 7107 46641084
Application site vesicles 16.95 10.28 12 37859 1452 46646739
Lagophthalmos 16.87 10.28 7 37864 288 46647903
Drug abuse 16.77 10.28 16 37855 63392 46584799
Application site irritation 16.76 10.28 13 37858 1806 46646385
Dermatitis contact 16.28 10.28 26 37845 8097 46640094
Injection related reaction 15.99 10.28 8 37863 510 46647681
Glossodynia 15.97 10.28 8 37863 44365 46603826
Lymphopenia 15.85 10.28 37 37834 15256 46632935
Abdominal discomfort 15.78 10.28 66 37805 151099 46497092
Urine abnormality 15.72 10.28 21 37850 5573 46642618
Infusion related reaction 15.64 10.28 37 37834 101171 46547020
Porphyria acute 15.13 10.28 7 37864 375 46647816
Urinary tract infection pseudomonal 14.78 10.28 9 37862 844 46647347
Anaphylactic reaction 14.52 10.28 13 37858 53099 46595092
Urine odour abnormal 14.51 10.28 19 37852 4943 46643248
Thyroglobulin increased 14.49 10.28 4 37867 45 46648146
Neutrophil percentage increased 14.22 10.28 14 37857 2673 46645518
Skin irritation 14.16 10.28 23 37848 7264 46640927
Resting tremor 13.95 10.28 8 37863 672 46647519
Decubitus ulcer 13.78 10.28 27 37844 9871 46638320
Pyelonephritis 13.62 10.28 35 37836 15322 46632869
Product complaint 13.34 10.28 30 37841 12071 46636120
Dizziness 13.08 10.28 365 37506 340049 46308142
Stress urinary incontinence 13.05 10.28 12 37859 2104 46646087
Pregnancy 13.04 10.28 3 37868 27134 46621057
Arthralgia 12.93 10.28 213 37658 364390 46283801
Bone marrow failure 12.89 10.28 4 37867 29665 46618526
Impaired self-care 12.85 10.28 11 37860 1757 46646434
Open fracture 12.84 10.28 6 37865 329 46647862
Hepatic function abnormal 12.70 10.28 6 37865 34415 46613776
Repetitive strain injury 12.60 10.28 5 37866 183 46648008
Product closure removal difficult 12.53 10.28 3 37868 18 46648173
Intentional overdose 12.38 10.28 21 37850 64923 46583268
Memory impairment 12.36 10.28 106 37765 77231 46570960
Prescribed underdose 12.31 10.28 29 37842 12024 46636167
Nephrolithiasis 12.07 10.28 56 37815 32995 46615196
Drug withdrawal syndrome neonatal 12.02 10.28 11 37860 1917 46646274
Walking aid user 11.95 10.28 17 37854 4783 46643408
Nausea 11.95 10.28 447 37424 687007 45961184
Body height decreased 11.86 10.28 25 37846 9627 46638564
Mixed incontinence 11.75 10.28 4 37867 94 46648097
Interstitial lung disease 11.67 10.28 16 37855 53933 46594258
Incision site pruritus 11.67 10.28 3 37868 25 46648166
Hallucinations, mixed 11.67 10.28 15 37856 3834 46644357
Vertigo 11.51 10.28 77 37794 51971 46596220
Haemoglobin urine present 11.47 10.28 7 37864 659 46647532
Intestinal pseudo-obstruction 11.46 10.28 7 37864 660 46647531
Basophil count decreased 11.34 10.28 4 37867 105 46648086
Dysarthria 11.19 10.28 60 37811 37438 46610753
Klebsiella test positive 11.14 10.28 8 37863 989 46647202
Anaemia folate deficiency 11.13 10.28 5 37866 250 46647941
Tri-iodothyronine increased 11.03 10.28 4 37867 114 46648077
Coordination abnormal 10.81 10.28 26 37845 10923 46637268
Urinary tract disorder 10.54 10.28 11 37860 2249 46645942
Visual impairment 10.44 10.28 91 37780 66598 46581593
Incision site erythema 10.42 10.28 5 37866 291 46647900

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary tract infection 150.68 13.02 175 13246 73484 29865573
Dry mouth 82.76 13.02 74 13347 22776 29916281
Fall 69.95 13.02 209 13212 181663 29757394
Multiple sclerosis relapse 64.51 13.02 47 13374 10815 29928242
Confusional state 63.64 13.02 167 13254 134667 29804390
Multiple sclerosis 46.72 13.02 33 13388 7234 29931823
Muscle spasticity 41.56 13.02 27 13394 5161 29933896
Disorganised speech 34.90 13.02 12 13409 537 29938520
Urinary retention 30.89 13.02 54 13367 32863 29906194
Bladder spasm 26.04 13.02 11 13410 867 29938190
Daydreaming 25.01 13.02 9 13412 461 29938596
Constipation 24.62 13.02 108 13313 112798 29826259
Completed suicide 23.09 13.02 97 13324 99395 29839662
Hallucination 21.28 13.02 59 13362 49000 29890057
Urosepsis 21.04 13.02 25 13396 10707 29928350
Syncope 19.87 13.02 83 13338 84820 29854237
Urinary incontinence 18.84 13.02 30 13391 16910 29922147
Delirium 18.76 13.02 50 13371 40581 29898476
Nephrolithiasis 18.63 13.02 37 13384 24773 29914284
Pollakiuria 17.52 13.02 29 13392 16877 29922180
Gait disturbance 17.41 13.02 73 13348 74704 29864353
Interstitial lung disease 17.41 13.02 3 13418 60194 29878863
Intestinal pseudo-obstruction 17.29 13.02 9 13412 1137 29937920
Dizziness 17.01 13.02 147 13274 194762 29744295
Neurogenic bladder 16.85 13.02 10 13411 1629 29937428
Decubitus ulcer 16.70 13.02 19 13402 7769 29931288
Granulocytopenia 16.52 13.02 17 13404 6209 29932848
Cognitive disorder 16.22 13.02 34 13387 23656 29915401
Rib hypoplasia 15.31 13.02 3 13418 12 29939045
Pulmonary hypoplasia 14.81 13.02 6 13415 425 29938632
Amnesia 14.48 13.02 33 13388 24288 29914769
Vision blurred 14.08 13.02 46 13375 41770 29897287
Implant site erosion 14.05 13.02 4 13417 95 29938962
Muscular weakness 13.94 13.02 61 13360 63584 29875473
Haematuria 13.93 13.02 48 13373 44786 29894271
Tongue haemorrhage 13.92 13.02 6 13415 497 29938560
Mental status changes 13.59 13.02 42 13379 37037 29902020
Hypertonic bladder 13.54 13.02 7 13414 872 29938185
Asthenia 13.52 13.02 155 13266 221135 29717922
Abnormal behaviour 13.34 13.02 33 13388 25590 29913467
Hepatitis acute 13.06 13.02 16 13405 7067 29931990
Bladder catheterisation 13.06 13.02 6 13415 578 29938479

Pharmacologic Action:

SourceCodeDescription
ATC G04BD04 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs for urinary frequency and incontinence
FDA MoA N0000000125 Cholinergic Muscarinic Antagonists
FDA EPC N0000175700 Cholinergic Muscarinic Antagonist
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D010276 Parasympatholytics
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D064804 Urological Agents
CHEBI has role CHEBI:36333 local anesthetics
CHEBI has role CHEBI:38215 calcium channel blockers
CHEBI has role CHEBI:48876 antimuskarinika
CHEBI has role CHEBI:50370 parasympatholytics
CHEBI has role CHEBI:51371 muscle relaxants
CHEBI has role CHEBI:53784 antispasmodics

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Urgent desire to urinate indication 75088002
Urge incontinence of urine indication 87557004
Bladder muscle dysfunction - overactive indication 236633002
Neurogenic bladder indication 398064005
Increased Urinary Frequency indication
Sinus tachycardia contraindication 11092001
Severe chronic ulcerative colitis contraindication 14311001
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Paralytic ileus contraindication 55525008 DOID:8442
Ulcerative colitis contraindication 64766004 DOID:8577
Hiatal hernia contraindication 84089009 DOID:12642
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Gastrointestinal obstruction contraindication 126765001
Gastroesophageal reflux disease contraindication 235595009 DOID:8534
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Drowsy contraindication 271782001
Gastric retention contraindication 307227006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009
Gastrointestinal hypomotility contraindication 421807004

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.67 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST Ki 9 CHEMBL DRUG LABEL
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 9.11 CHEMBL DRUG LABEL
5-hydroxytryptamine receptor 2B GPCR Ki 6.30 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.84 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 7.17 DRUG MATRIX
Cytochrome P450 2C19 Enzyme IC50 6.22 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 8.09 CHEMBL
Muscarinic acetylcholine receptor M4 GPCR Ki 8.44 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.99 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 7.85 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.59 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.09 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 8.23 CHEMBL
Muscarinic acetylcholine receptor M3 GPCR Ki 9.02 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 8.16 CHEMBL

External reference:

IDSource
4018815 VUID
N0000147118 NUI
D00465 KEGG_DRUG
1508-65-2 SECONDARY_CAS_RN
4018815 VANDF
4019869 VANDF
C0591395 UMLSCUI
CHEBI:7856 CHEBI
CHEMBL1133 ChEMBL_ID
CHEMBL1231 ChEMBL_ID
DB01062 DRUGBANK_ID
C005419 MESH_SUPPLEMENTAL_RECORD_UI
4634 PUBCHEM_CID
359 IUPHAR_LIGAND_ID
1354 INN_ID
K9P6MC7092 UNII
151651 RXNORM
180 MMSL
28244 MMSL
4610 MMSL
46359 MMSL
5214 MMSL
d00328 MMSL
001768 NDDF
004715 NDDF
31815007 SNOMEDCT_US
35768004 SNOMEDCT_US
372717000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
GELNIQUE HUMAN PRESCRIPTION DRUG LABEL 1 0023-5812 GEL 100 mg TRANSDERMAL NDA 27 sections
GELNIQUE HUMAN PRESCRIPTION DRUG LABEL 1 0023-5861 GEL 100 mg TRANSDERMAL NDA 27 sections
OXYTROL HUMAN PRESCRIPTION DRUG LABEL 1 0023-6153 PATCH 3.90 mg TRANSDERMAL NDA 26 sections
Oxytrol for Women HUMAN OTC DRUG LABEL 1 0023-9637 PATCH 3.90 mg TRANSDERMAL NDA 14 sections
OXYBUTYNIN CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0121-0671 SYRUP 5 mg ORAL ANDA 18 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-4975 TABLET 5 mg ORAL ANDA 24 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-3512 TABLET 5 mg ORAL ANDA 21 sections
oxybutynin chloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7521 TABLET, EXTENDED RELEASE 15 mg ORAL NDA 23 sections
oxybutynin HUMAN PRESCRIPTION DRUG LABEL 1 0615-8219 TABLET, FILM COATED, EXTENDED RELEASE 5 mg ORAL ANDA 24 sections
Oxybutynin HUMAN PRESCRIPTION DRUG LABEL 1 0615-8220 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 24 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0038 TABLET 5 mg ORAL ANDA 23 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-2821 TABLET 5 mg ORAL ANDA 21 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6570 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 25 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-609 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 29 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-610 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-611 TABLET, EXTENDED RELEASE 15 mg ORAL ANDA 29 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-640 TABLET 5 mg ORAL ANDA 23 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-518 TABLET 5 mg ORAL ANDA 24 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-559 TABLET 5 mg ORAL ANDA 21 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-201 TABLET 5 mg ORAL ANDA 22 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 14539-653 TABLET 5 mg ORAL ANDA 13 sections
oxybutynin chloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-317 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 26 sections
oxybutynin chloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-318 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
oxybutynin chloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-319 TABLET, EXTENDED RELEASE 15 mg ORAL ANDA 26 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0092 SYRUP 5 mg ORAL ANDA 17 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0149 SYRUP 5 mg ORAL ANDA 21 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-1491 SOLUTION 5 mg ORAL ANDA 23 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-406 TABLET 5 mg ORAL ANDA 23 sections
Oxybutynin Chloride Human Prescription Drug Label 1 27241-155 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 25 sections
Oxybutynin Chloride Human Prescription Drug Label 1 27241-156 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 25 sections